CA3095308A1 - Compositions and methods for treating renal injury - Google Patents

Compositions and methods for treating renal injury Download PDF

Info

Publication number
CA3095308A1
CA3095308A1 CA3095308A CA3095308A CA3095308A1 CA 3095308 A1 CA3095308 A1 CA 3095308A1 CA 3095308 A CA3095308 A CA 3095308A CA 3095308 A CA3095308 A CA 3095308A CA 3095308 A1 CA3095308 A1 CA 3095308A1
Authority
CA
Canada
Prior art keywords
renal
alkyl
group
pgdh
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095308A
Other languages
English (en)
French (fr)
Inventor
Sanford Markowitz
Ki Beom Bae
Hye Jung Kim
Sun-Hee Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inje Industry Academic Cooperation Foundation
Case Western Reserve University
Original Assignee
Inje Industry Academic Cooperation Foundation
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inje Industry Academic Cooperation Foundation, Case Western Reserve University filed Critical Inje Industry Academic Cooperation Foundation
Publication of CA3095308A1 publication Critical patent/CA3095308A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3095308A 2018-04-04 2019-04-04 Compositions and methods for treating renal injury Pending CA3095308A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652769P 2018-04-04 2018-04-04
US62/652,769 2018-04-04
PCT/US2019/025812 WO2019195565A1 (en) 2018-04-04 2019-04-04 Compositions and methods for treating renal injury

Publications (1)

Publication Number Publication Date
CA3095308A1 true CA3095308A1 (en) 2019-10-10

Family

ID=68101395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095308A Pending CA3095308A1 (en) 2018-04-04 2019-04-04 Compositions and methods for treating renal injury

Country Status (7)

Country Link
US (3) US20210100779A1 (enExample)
EP (1) EP3781154A4 (enExample)
JP (1) JP7426941B2 (enExample)
CN (1) CN112739344A (enExample)
AU (2) AU2019247838A1 (enExample)
CA (1) CA3095308A1 (enExample)
WO (1) WO2019195565A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
US12616681B2 (en) 2019-04-04 2026-05-05 Case Western Reserve University Compositions and methods for treating renal injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187221A1 (en) * 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP6203820B2 (ja) * 2012-04-16 2017-09-27 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
JP2018511616A (ja) 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
US12616681B2 (en) 2019-04-04 2026-05-05 Case Western Reserve University Compositions and methods for treating renal injury

Also Published As

Publication number Publication date
US20210100779A1 (en) 2021-04-08
AU2025201403A1 (en) 2025-03-20
EP3781154A1 (en) 2021-02-24
EP3781154A4 (en) 2022-02-23
WO2019195565A1 (en) 2019-10-10
AU2019247838A1 (en) 2020-10-15
JP2021519797A (ja) 2021-08-12
CN112739344A (zh) 2021-04-30
JP7426941B2 (ja) 2024-02-02
US20250325524A1 (en) 2025-10-23
US20240024297A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US20250325524A1 (en) Compositions and methods for treating renal injury
US12616681B2 (en) Compositions and methods for treating renal injury
Li et al. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis
Ahmed et al. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation
US20230310390A1 (en) Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration
Abdel-Aziz et al. 1-(4-Methoxyphenyl)-5-(3, 4, 5-trimethoxyphenyl)-1H-1, 2, 4-triazole-3-carboxamides: Synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity
US20240279201A1 (en) Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease
WO2019010482A1 (en) COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION
US20240366568A1 (en) Compositions and methods for treating tissue injury
JP5153621B2 (ja) Ｓｈｐ−２阻害剤、それらを含む薬剤組成物及びホスファターゼ媒介性疾患を治療するためのその使用
CN106164059A (zh) 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
HK40052492A (en) Compositions and methods for treating renal injury
KR101373912B1 (ko) Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
HUP0001888A2 (hu) 5HT1 Agonistát és COX-2 inhibitort vagy NSAID-t tartalmazó gyógyszerészeti összetétel migrén kezelésére
WO2023023867A1 (en) Compounds for reducing cholesterol and treating liver and kidney disease
WO2014012000A2 (en) No-releasing guanidine-coxib anti-cancer agents
US20240139214A1 (en) Agent for suppressing il-31 production and pharmaceutical composition containing the same
KR102241064B1 (ko) 신규한 인돌 유도체 및 이를 포함하는 염증성 질환 예방 또는 치료용 조성물
WO2023066127A1 (zh) 速激肽受体3抑制剂的用途
WO2026006830A1 (en) Compositions and methods of treating diseases and disorders characterized by blood-brain barrier deterioration or reactive oxygen species generation
Calatayud et al. Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240306

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250711

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260402